PEOPLE - Bioject (US) makes appointment:
This article was originally published in Clinica
Executive Summary
Developer of needle-free drug delivery systems Bioject (Bedminster, New Jersey) has appointed Eric Mishkin as senior vice-president and chief scientific officer. Dr Mishkin, who has over 25 years of experience in immunology research and microbiology, most recenly served as director of immunology research at Wyeth-Ayerst. It has also announced the appointment of Chris Pugh, who has over 10 years of product and business development experience, as director of business development.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.